Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Epizyme, Inc. stock logo
EPZM
Epizyme
$1.47
$1.47
$0.41
$5.80
$247.44M-0.413.23 million shs7,960 shs
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
$329.83
$327.01
$158.38
$329.99
$12.58B1.18832,048 shs5 shs
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$80.14
-0.2%
$84.16
$64.94
$90.04
$3.97B0.43305,577 shs562,850 shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$23.21
-0.2%
$25.32
$11.16
$27.64
$1.08B0.48918,532 shs584,349 shs
Xencor, Inc. stock logo
XNCR
Xencor
$8.30
+2.9%
$8.80
$7.16
$27.24
$574.35M0.85679,156 shs913,939 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Epizyme, Inc. stock logo
EPZM
Epizyme
0.00%0.00%0.00%0.00%0.00%
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
0.00%0.00%0.00%0.00%0.00%
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
+0.54%-5.26%-6.42%-6.91%+18.59%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
-2.72%-5.56%-9.85%-6.59%-18.31%
Xencor, Inc. stock logo
XNCR
Xencor
+2.67%-2.42%+4.81%-17.82%-57.57%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Epizyme, Inc. stock logo
EPZM
Epizyme
N/AN/AN/AN/AN/AN/AN/AN/A
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
4.2185 of 5 stars
2.34.00.03.52.91.71.9
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
3.5455 of 5 stars
2.22.00.03.92.72.50.6
Xencor, Inc. stock logo
XNCR
Xencor
4.0426 of 5 stars
3.42.00.03.92.20.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Epizyme, Inc. stock logo
EPZM
Epizyme
0.00
N/AN/AN/A
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
0.00
N/AN/AN/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
2.50
Moderate Buy$93.3316.46% Upside
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
2.33
Hold$26.4413.94% Upside
Xencor, Inc. stock logo
XNCR
Xencor
2.75
Moderate Buy$28.00237.35% Upside

Current Analyst Ratings Breakdown

Latest PCRX, EPZM, KRTX, PBH, and XNCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$32.00 ➝ $30.00
5/8/2025
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
5/8/2025
Xencor, Inc. stock logo
XNCR
Xencor
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$22.00 ➝ $6.00
4/30/2025
Xencor, Inc. stock logo
XNCR
Xencor
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$31.00
4/21/2025
Xencor, Inc. stock logo
XNCR
Xencor
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
4/8/2025
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
4/8/2025
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$48.00 ➝ $65.00
(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Epizyme, Inc. stock logo
EPZM
Epizyme
$37.43M6.61N/AN/A($0.54) per share-2.72
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
$654K19,239.07N/AN/A$33.24 per share9.92
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$1.14B3.48$5.20 per share15.41$37.04 per share2.16
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$700.97M1.53$4.31 per share5.39$16.86 per share1.38
Xencor, Inc. stock logo
XNCR
Xencor
$110.49M5.35N/AN/A$9.63 per share0.86
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Epizyme, Inc. stock logo
EPZM
Epizyme
-$251.12M-$1.72N/AN/AN/A-391.90%-2,459.33%-69.74%N/A
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
-$433.68M-$11.72N/AN/AN/AN/A-31.63%-30.38%N/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$214.60M$4.2918.6816.842.4118.86%12.87%6.78%8/6/2025 (Estimated)
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
-$99.56M-$2.28N/A9.03N/A-14.78%13.78%7.00%7/29/2025 (Estimated)
Xencor, Inc. stock logo
XNCR
Xencor
-$232.62M-$3.06N/AN/AN/A-181.17%-31.94%-22.19%8/4/2025 (Estimated)

Latest PCRX, EPZM, KRTX, PBH, and XNCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/29/2025Q2 2025
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$0.73N/AN/AN/A$183.11 millionN/A
5/8/2025Q4 2025
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
$1.30$1.32+$0.02$1.00$289.36 million$296.52 million
5/8/2025Q1 2025
Xencor, Inc. stock logo
XNCR
Xencor
-$0.60-$0.66-$0.06-$0.66$23.44 million$32.73 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Epizyme, Inc. stock logo
EPZM
Epizyme
N/AN/AN/AN/AN/A
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/AN/AN/AN/AN/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
N/AN/AN/AN/AN/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
N/AN/AN/AN/AN/A
Xencor, Inc. stock logo
XNCR
Xencor
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Epizyme, Inc. stock logo
EPZM
Epizyme
N/A
5.35
5.19
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/A
19.31
19.31
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
0.55
4.20
2.82
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.48
2.41
1.99
Xencor, Inc. stock logo
XNCR
Xencor
0.16
5.89
5.89

Institutional Ownership

CompanyInstitutional Ownership
Epizyme, Inc. stock logo
EPZM
Epizyme
76.45%
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
N/A
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
99.95%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
99.73%
Xencor, Inc. stock logo
XNCR
Xencor
N/A

Insider Ownership

CompanyInsider Ownership
Epizyme, Inc. stock logo
EPZM
Epizyme
23.40%
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
13.20%
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
1.60%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
6.40%
Xencor, Inc. stock logo
XNCR
Xencor
4.76%
CompanyEmployeesShares OutstandingFree FloatOptionable
Epizyme, Inc. stock logo
EPZM
Epizyme
250168.33 million128.97 millionOptionable
Karuna Therapeutics, Inc. stock logo
KRTX
Karuna Therapeutics
33938.15 million33.16 millionOptionable
Prestige Consumer Healthcare Inc. stock logo
PBH
Prestige Consumer Healthcare
54049.42 million48.62 millionOptionable
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
72046.29 million43.33 millionOptionable
Xencor, Inc. stock logo
XNCR
Xencor
28071.17 million67.78 millionOptionable

Recent News About These Companies

Xencor, Inc. (XNCR) Latest Stock News & Headlines - Yahoo Finance
Xencor Reports First Quarter 2025 Financial Results
Xencor initiated with an Outperform at William Blair
Xencor participates in a conference call with JPMorgan

New MarketBeat Followers Over Time

Media Sentiment Over Time

Epizyme stock logo

Epizyme NASDAQ:EPZM

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Karuna Therapeutics stock logo

Karuna Therapeutics NASDAQ:KRTX

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Prestige Consumer Healthcare stock logo

Prestige Consumer Healthcare NYSE:PBH

$80.14 -0.18 (-0.22%)
Closing price 03:59 PM Eastern
Extended Trading
$80.18 +0.04 (+0.05%)
As of 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Pacira BioSciences stock logo

Pacira BioSciences NASDAQ:PCRX

$23.21 -0.04 (-0.17%)
Closing price 04:00 PM Eastern
Extended Trading
$23.22 +0.01 (+0.04%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Xencor stock logo

Xencor NASDAQ:XNCR

$8.30 +0.23 (+2.85%)
Closing price 04:00 PM Eastern
Extended Trading
$8.34 +0.04 (+0.48%)
As of 06:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.